"Aika" announced the completion of a round A financing over 100 million yuan

DONEWS News on September 26. Shandong Aikoda Biotechnology Co., Ltd., which has stopped hemostasis and thrombosis, announced the completion of exceeding 100 million yuan in Series A financing, which was jointly invested by Yida Capital and CITIC Medical Fund.

Public information shows that Shandong Aikeda Biotechnology Co., Ltd. was established on January 17, 2017. It is a high -tech enterprise specializing in external diagnostic instruments and supporting reagents. It is headquartered in Jinan, Quancheng. The company integrates R & D, production, sales and technical services, and has branches in Beijing, Shanghai, Hangzhou, Suzhou and other places. Koda products cover the coagulation detection system, specific fixed protein detection system, reproductive detection system and immunoaged detection system, which can provide comprehensive and high -quality solutions for medical laboratories. The company has continuously introduced international advanced technology and high -end talents, carried out production, learning and research cooperation in several domestic universities, and building clinical cooperation bases with a number of triple hospitals to effectively improve the clinical effectiveness of products.

The company's core product ADX-E1 is designed for GW-3000, which is specifically designed for Aika fully automatic coagulation analyzer GW-3000. The ADX-E1 fully automatic coagulation flow line consists of automatic orbital unit, automatic centrifugal unit, GW-3000 fully automatic coagulation analysis system, ACCURDX reagent system, and ACCURDX intelligent data management system.

In the case of the same configuration and the same detection speed, the ADX-E1 is the smallest automatic coagulation flow line in the market (equipped with 1 main control computer, 2 GW-3000, 1 separation and re-examination weekly turnover The ADX-E1 of the module covers only 4 square meters). The PT detection speed of the GW-6000 stand-alone machine is as high as 600 test/hour, and the D-di-germ detection speed is as high as 300 test/hour. The GW-6000 has the functions of all coagulation detection methods such as optical method, magnetic bead method, and gathering method. Through the classic magnetic bead method, the interference of the test results of the detection results is completely eliminated by the color of hemolysis, chylite, and jaundice.

The smart bud science innovation assessment platform shows that Ekida's science and technology innovation capabilities in the biomedical engineering industry are rated as a Class A. At present, there are more than 50 patent applications, which are mainly focused on related technologies such as analyzers, kits, and coagulation instruments.

- END -